Collectively, these studies underscore the critical role of galectin-3 in mediating cardiac fibrosis and diastolic dysfunction, highlighting its potential as a therapeutic target for managing HFpEF and other cardiac conditions characterized by impaired diastolic function. Here, LGALS3 is linked to fibrosis.